Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Goldenwell Biotech (GWLL) Gross Margin (2021 - 2024)

Goldenwell Biotech (GWLL) has disclosed Gross Margin for 4 consecutive years, with 53.8% as the latest value for Q4 2024.

  • For the quarter ending Q4 2024, Gross Margin rose 2572.0% year-over-year to 53.8%, compared with a TTM value of 39503.16% through Sep 2025, down 3952884.0%, and an annual FY2024 reading of 46.04%, up 977.0% over the prior year.
  • Gross Margin was 53.8% for Q4 2024 at Goldenwell Biotech, up from 23.57% in the prior quarter.
  • Across five years, Gross Margin topped out at 53.8% in Q4 2024 and bottomed at 23.57% in Q2 2024.
  • Average Gross Margin over 4 years is 47.47%, with a median of 52.53% recorded in 2021.
  • Peak annual rise in Gross Margin hit 2572bps in 2024, while the deepest fall reached -2643bps in 2024.
  • Year by year, Gross Margin stood at 52.54% in 2021, then increased by 0bps to 52.71% in 2022, then tumbled by -47bps to 28.08% in 2023, then skyrocketed by 92bps to 53.8% in 2024.
  • Business Quant data shows Gross Margin for GWLL at 53.8% in Q4 2024, 23.57% in Q2 2024, and 28.08% in Q4 2023.